Hematologic and molecular response to peg-IFN-α-2a
. | . | . | . | Hematologic response . | . | Molecular response . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Sex . | Age . | Follow-up, mo . | Type of HR . | Time to HR, mo . | Initial % V617F . | % V617F at time of HR . | Minimal % V617F . | % of V617F decrease . | ||||
| 1 | M | 35 | 18 | CR | 3 | 50 | 50 | 5 | 90 | ||||
| 2 | M | 44 | 17 | CR | 3 | 10 | 10 | 5 | 50 | ||||
| 3 | F | 64 | 17 | CR | 3 | 50 | 50 | 50 | 0 | ||||
| 4 | F | 50 | 16 | CR | 3 | 100 | 80 | 45 | 55 | ||||
| 5 | F | 56 | 16 | CR | 3 | 40 | 40 | 20 | 50 | ||||
| 6 | F | 52 | 15 | CR | 3 | 50 | 50 | 0 | 100 | ||||
| 7 | M | 43 | 15 | PR | 6 | 100 | 50 | 45 | 55 | ||||
| 8 | F | 22 | 15 | CR | 6 | 25 | 25 | 10 | 60 | ||||
| 9 | F | 59 | 15 | CR | 3 | 100 | 85 | 50 | 50 | ||||
| 10 | M | 47 | 13 | CR | 3 | 70 | 55 | 45 | 36 | ||||
| 11 | F | 51 | 13 | CR | 3 | 40 | 40 | 40 | 0 | ||||
| 12 | F | 47 | 13 | CR | 3 | 10 | 10 | 5 | 50 | ||||
| 13 | F | 65 | 13 | CR | 6 | 40 | NA | 25 | 25 | ||||
| 14 | F | 56 | 13 | CR | 3 | 40 | 25 | 20 | 50 | ||||
| 15 | F | 46 | 13 | CR | 3 | 45 | 45 | 30 | 33 | ||||
| 16 | M | 50 | 12 | CR | 3 | 80 | NA | 45 | 44 | ||||
| 17 | F | 42 | 12 | PR | 3 | 45 | 35 | 25 | 44 | ||||
| 18 | F | 43 | 12 | CR | 3 | 60 | 60 | 50 | 17 | ||||
| 19 | F | 30 | 11 | CR | 6 | 40 | 20 | 20 | 50 | ||||
| 20 | F | 38 | 9 | CR | 6 | 35 | NA | 20 | 43 | ||||
| 21 | F | 54 | 8 | CR | 6 | 20 | 10 | 10 | 50 | ||||
| 22 | F | 40 | 8 | CR | 6 | 10 | 10 | 10 | 0 | ||||
| 23 | M | 28 | 7 | CR | 3 | 40 | 5 | 5 | 88 | ||||
| 24 | M | 51 | 7 | CR | 3 | 65 | 45 | 40 | 38 | ||||
| 25 | F | 30 | 7 | PR | 3 | 50 | 40 | 40 | 20 | ||||
| 26 | M | 60 | 6 | PR | 3 | 65 | 50 | 50 | 23 | ||||
| 27 | F | 54 | 6 | CR | 3 | 45 | NA | 10 | 78 | ||||
. | . | . | . | Hematologic response . | . | Molecular response . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Sex . | Age . | Follow-up, mo . | Type of HR . | Time to HR, mo . | Initial % V617F . | % V617F at time of HR . | Minimal % V617F . | % of V617F decrease . | ||||
| 1 | M | 35 | 18 | CR | 3 | 50 | 50 | 5 | 90 | ||||
| 2 | M | 44 | 17 | CR | 3 | 10 | 10 | 5 | 50 | ||||
| 3 | F | 64 | 17 | CR | 3 | 50 | 50 | 50 | 0 | ||||
| 4 | F | 50 | 16 | CR | 3 | 100 | 80 | 45 | 55 | ||||
| 5 | F | 56 | 16 | CR | 3 | 40 | 40 | 20 | 50 | ||||
| 6 | F | 52 | 15 | CR | 3 | 50 | 50 | 0 | 100 | ||||
| 7 | M | 43 | 15 | PR | 6 | 100 | 50 | 45 | 55 | ||||
| 8 | F | 22 | 15 | CR | 6 | 25 | 25 | 10 | 60 | ||||
| 9 | F | 59 | 15 | CR | 3 | 100 | 85 | 50 | 50 | ||||
| 10 | M | 47 | 13 | CR | 3 | 70 | 55 | 45 | 36 | ||||
| 11 | F | 51 | 13 | CR | 3 | 40 | 40 | 40 | 0 | ||||
| 12 | F | 47 | 13 | CR | 3 | 10 | 10 | 5 | 50 | ||||
| 13 | F | 65 | 13 | CR | 6 | 40 | NA | 25 | 25 | ||||
| 14 | F | 56 | 13 | CR | 3 | 40 | 25 | 20 | 50 | ||||
| 15 | F | 46 | 13 | CR | 3 | 45 | 45 | 30 | 33 | ||||
| 16 | M | 50 | 12 | CR | 3 | 80 | NA | 45 | 44 | ||||
| 17 | F | 42 | 12 | PR | 3 | 45 | 35 | 25 | 44 | ||||
| 18 | F | 43 | 12 | CR | 3 | 60 | 60 | 50 | 17 | ||||
| 19 | F | 30 | 11 | CR | 6 | 40 | 20 | 20 | 50 | ||||
| 20 | F | 38 | 9 | CR | 6 | 35 | NA | 20 | 43 | ||||
| 21 | F | 54 | 8 | CR | 6 | 20 | 10 | 10 | 50 | ||||
| 22 | F | 40 | 8 | CR | 6 | 10 | 10 | 10 | 0 | ||||
| 23 | M | 28 | 7 | CR | 3 | 40 | 5 | 5 | 88 | ||||
| 24 | M | 51 | 7 | CR | 3 | 65 | 45 | 40 | 38 | ||||
| 25 | F | 30 | 7 | PR | 3 | 50 | 40 | 40 | 20 | ||||
| 26 | M | 60 | 6 | PR | 3 | 65 | 50 | 50 | 23 | ||||
| 27 | F | 54 | 6 | CR | 3 | 45 | NA | 10 | 78 | ||||
HR indicates hematologic response; CR, hematologic complete response; PR, hematologic partial response; NA, sample not available at that time point.